
Newbury Pharmaceuticals Q2 - A bump in the road

Redeye provides a research update following the Q2 report published by Newbury yesterday. As the company follows up the impressive Q1 figures with some rather modest sales figures, we make some downward adjustments to our estimates for future sales growth. Having also adjusted for the dilution effect from the recent directed share issue, we revise our base case valuation to SEK8 (9).

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Newbury Pharmaceuticals Q2 - A bump in the road](#)